CD3-CD16+ (NK) cells are rapidly and markedly affected by interferon β 1b (INFβ1b) therapy in relapsing-remitting MS patients

Authors :: A.M. Ferrarini
Paola Perini
S. Sivieri
P. Bulian
Paolo Gallo
Giovanni Biasi
Source :: Journal of Neuroimmunology. 90:97
Publication Year :: 1998
Publisher :: Elsevier BV, 1998.

Subjects :: biology
business.industry
CD3
Immunology
CD16
Interferon β 1b
Neurology
Relapsing remitting
biology.protein
Immunology and Allergy
Medicine
Neurology (clinical)
business

Full Text Access

Tools